Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib + SHR-1701 in EGFR-mutated NSCLC
NCT05503888Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of retlirafusp alfa in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Incidence and severity of treatment-related adverse events and serious adverse events and 1 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05503888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503888.